GlassScriptPhysician profile
Mohammed Ali Tirgan
NPI 1174520357
$9,441.10
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,237 · 2020: $3,205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $4,404.98 | 2019 | |
| Pharmacosmos Therapeutics INC. | $3,150.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $192.26 | 2019 | |
| Incyte Corporation | $185.86 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $160.81 | 2019 | |
| Amgen INC. | $124.86 | 2019 | |
| Rigel Pharmaceuticals, INC. | $124.48 | 2019 | |
| Lilly USA, LLC | $121.84 | 2019 | |
| Janssen Biotech, INC. | $113.19 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $80.56 | 2019 | |
| Genzyme Corporation | $73.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.74 | 2019 | |
| Merck Sharp & Dohme LLC | $71.32 | 2019 | |
| Seagen INC. | $64.24 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.55 | 2019 | |
| Genentech USA, INC. | $44.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.14 | 2019 | |
| Eisai INC. | $33.65 | 2019 | |
| Emd Serono, INC. | $33.04 | 2019 | |
| Beigene USA, INC. | $32.84 | 2020 | |
| Gilead Sciences, INC. | $28.67 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $22.86 | 2019 | |
| Clovis Oncology, INC. | $21.66 | 2020 | |
| Celgene Corporation | $21.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.95 | 2019 | |
| Puma Biotechnology, INC. | $16.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Tirgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.